Last reviewed · How we verify
NCT06036030: MCMPFPB
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
Phase 2 trial testing Dihydroartemisinin in Malaria,Falciparum in 50 participants. Completed in 16 April 2019.
16 April 2019
Quick facts
| Lead sponsor | Syamsudin Abdillah,Ph.D, Pharm D |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 11 January 2019 |
| Primary completion | 16 April 2019 |
| Estimated completion | 16 April 2019 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- Dihydroartemisinin — full drug profile →
- Piperaquine — full drug profile →
- Primaquine — full drug profile →
- Momordica Charantia Extract — full drug profile →
Conditions studied
- Malaria,Falciparum — all drugs for Malaria,Falciparum →
- Malaria, Vivax — all drugs for Malaria, Vivax →
- Malaria — all drugs for Malaria →
- Infections — all drugs for Infections →
Sponsor
Syamsudin Abdillah,Ph.D, Pharm D — full company profile →
Who can join
Adults 15 to 60, any sex, with Malaria,Falciparum or Malaria, Vivax. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparing the efficacy of the combination treatment of bitter melon fruit extract (Momordica charantia) with primaquine (MC+PQ) against the combination of dihydroartemisinin + piperaquine + primaquine (DHP+PQ) on patients with Plasmodium falciparum and Plasmodium vivax without complications in Manokwari, West Papua, Indonesia. The research was conducted from January 2019 to April 2019 at Manokwari Regional General Hospital, West Papua. Open label, 2 parallel randomized clinical studies with Plasmodium falciparum malaria patients without complications (Study 1) and patients with Plasmodium vivax malaria without complications (Study 2). The randomized clinical trial divided in 2 treatment groups, namely the MC+PQ and DHP+PQ. The Success of the treatment was determined by the combination of blood schizontocidal therapy in radical cure. The overall final assessed results were the average value of parasitological failure, hematological measurements, liver function, kidney function, blood lipid levels, blood glucose levels and adverse events until day 42.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06036030
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dihydroartemisinin
Trials testing the same drug.
- NCT06842524 — Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome · Phase 2 · recruiting
- NCT06417099 — Efficacy of Dihydroartemisinin for Treating PCOS · Phase 2 · completed
- NCT05829187 — Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patie · Phase 2 · completed
- NCT05465135 — The Effect of Dihydroartemisinin in PCOS · Phase 4 · completed
Other recruiting trials for Malaria,Falciparum
Currently open trials in the same condition.
- NCT06618885 — Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso · Phase 1 · active not recruiting
- NCT07009847 — An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine · recruiting
- NCT06524336 — Host Immune Dynamics Following Seasonal Malaria Chemoprevention in African Children · active not recruiting
- NCT05978037 — A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines · Phase 1, PHASE2 · active not recruiting
- NCT05790889 — A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso. · Phase 1, PHASE2 · recruiting
Other Syamsudin Abdillah,Ph.D, Pharm D trials
Trials by the same sponsor.
- NCT05829187 — Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patie · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06036030 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Syamsudin Abdillah,Ph.D, Pharm D
- Last refreshed: 13 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06036030.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing